2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOWill not start
Primary objective:* Demonstrating clinical superiority of MOD-4023 compared to placebo in terms of reduction of fat mass (FM) in adults persons with GHDSecondary objectives:* Determining the efficacy of MOD-4023 compared to placebo in other body…